Dexmedetomidine film for agitation associated with bipolar disorder


featured image

Dexmedetomidine sublingual film is in clinical development for the treatment of agitation associated with bipolar disorder. Bipolar disorder is mental health condition characterised by periods of mania and severe depression.

Interventions: Dexmedetomidine
Indications: Bipolar disorder
Therapeutic Areas: Mental and Behavioural Health
Year: 2022

Dexmedetomidine sublingual film is in clinical development for the treatment of agitation
associated with bipolar disorder. Bipolar disorder is mental health condition characterised by
periods of mania and severe depression. Agitation is a disruptive, and comorbid complication of
many chronic mental illnesses, including bipolar disorders. Agitation is described as excessive
motor activity associated with a feeling of inner tension. Activity which characterises an episode
of agitation is usually non-productive and repetitious. Although in clinical practice
pharmacological treatments are used, there are currently no NICE recommended treatment
options for agitation associated with bipolar disorder.